Article

NASP Launches Website to Combat Harmful DIR Fees Tops SPT Week in Review

Top news of the week from Specialty Pharmacy Times.

5. Treatment-Resistant Breast Cancer May Have Met Its Match with First-In-Class Drugs

The new compounds may lead to a highly effective, next-line treatment for estrogen receptor-positive breast cancer. Read more…

4. Influenza Triggers Relapse in Multiple Sclerosis

Upper respiratory infections cause immune cells to travel to the brain, prompting multiple sclerosis to relapse. Read more…

3. FDA Approves Acute Lymphoblastic Leukemia Drug

Inotuzumab ozogamicin (Besponsa) granted FDA approval to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read more…

2. Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis

Research finds that a robust pipeline of PsA agents will put pressure on Cosentyx. Read more…

1. NASP Launches Website to Combat Harmful DIR Fees

StopDIRfees.com provides education about direct and indirect remuneration fees. Read more…

Related Videos
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com
Child with cancer -- Image credit: Alexis Scholtz/peopleimages.com | stock.adobe.com
Image Credit: © Rawpixel.com - stock.adobe.com
Image Credit: © RandyJay - stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC